VERONICA CARRASCO: Open Payments
NPI 1407531817 · OMAHA, NE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,543 in 196 payments from 16 companies in 2025. Trend: 2023 $815 · 2024 $2,875 · 2025 $3,543
Food & beverage: $3,398Education: $145
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 22 | $462 |
| ABBVIE INC. | 32 | $450 |
| E.R. Squibb & Sons, L.L.C. | 25 | $391 |
| Otsuka America Pharmaceutical, Inc. | 16 | $378 |
| Vanda Pharmaceuticals Inc. | 15 | $363 |
| Alkermes, Inc. | 18 | $305 |
| Teva Pharmaceuticals USA, Inc. | 15 | $269 |
| Neurocrine BioSciences, Inc. | 16 | $243 |
| Lundbeck LLC | 10 | $182 |
| HARMONY BIOSCIENCES LLC | 6 | $143 |
Products named: CAPLYTA, VRAYLAR, COBENFY, REXULTI, ARISTADA, ABILIFY MAINTENA, INGREZZA, HETLIOZ.
Industry payments across NE — which companies pay providers there.
